Actavis Generics Company Intelligence Report

Summary

Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Contents

• Executive Summary
• Introduction
  • Products
  • Manufacturing sites
  • Actavis, ANDA Approvals 2006-09
  • Abrika Pharmaceuticals, ANDA Approvals 2002-07
  • Amide Pharmaceuticals, ANDA Approvals 2002-08
  • Recent product approvals
  • Gemcitabine (EU)
  • Actavis acquires Kadian from King
  • Bupropion (US)
  • Azithromycin (UK)
  • Atorvastatin (Serbia)
  • Epirubicin (US)
  • Ramipril (US)
  • Bicalutamide (UK, Germany and France)
  • Irinotecan hydrochloride
  • Actavis extends portfolio with FDA approvals
  • Financial results
  • Full Year Results, 2003-06 Fiscal Year to 31 December in euro millions
  • Total Revenues by Division - Fiscal 2006
  • Total Revenues by Region - Fiscal 2006
• Major developments
  • Actavis launches in Ireland
  • Actavis to restructure manufacturing operations in Bulgaria
  • Actavis opens R&D laboratories in Florida
  • Congressional Committee turns attention to Actavis recall
  • Keri Pharma rebranded as Actavis Hungary
  • Mergers, acquisitions and agreements
  • LPA to distribute Actavis' generic products in Algeria
  • ASKA Pharmaceutical and Actavis enter alliance and joint venture in Japan
  • Actavis expands presence in India
  • Actavis formally launches in France
  • Actavis signs distribution agreement with J&M Pharma
  • Actavis divests Polish products to Glenmark
  • Actavis signs distribution agreement with Generic Health in Australia
• ACTAVIS GENERIC COMPANIES ANALYSIS
  • Actavis acquires API manufacturing company in China
  • Actavis acquires Italian manufacturing site from Pfizer
  • Litigation
  • Endo and Penwest settle oxymorphone litigation with Actavis
  • Actavis challenges lisdexamphetamine NCE exclusivity
  • Warner Chilcott and Mayne Pharma add Actavis to doxycycline litigation
  • Justice Department seeks permanent injunction against Actavis
  • Endo and Penwest file oxymorphone suit against Actavis
  • Contact Details